department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

BioXcel Therapeutics, Inc. ($BTAI) · pharmadog

PUBLIC COMPANY

$BTAIBioXcel Therapeutics, Inc.

New Haven, CT, USupdated 32m ago

SEC EDGAR ↗Yahoo Finance ↗

community read0 votes

pipeline

2

marketed

1

phase 3

0

catalysts ytd

3

approvals ytd

1

recalls ytd

0

Pipeline(2)

pipeline depth2 products

1Marketed1Unknown

dexmedetomidine

Bipolar Disorder (Manic Depression)

Adrenergic receptor alpha-2

1 INDICATIONS AND USAGE IGALMI is indicated for the acute…

Adrenergic receptor alpha-2

Upcoming

no upcoming catalysts on record

Recent(90d)

drug shortage (1)

Dexmedetomidine Hydrochloride Injection shortage — Par Health, USA LLC

BioXcel Therapeutics, Inc.

view all catalysts →

🐶 Hiring Signal

No open roles indexed yet — view BioXcel Therapeutics, Inc. jobs →

News

no news has mentioned this company yet

identifiers

ticker

$BTAI

SEC CIK

0001720893

country

US

source

sec_tickers

top tags

mentioned in

0news items

entity-linker matched

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

$BTAI1.1000-20.29%

Data sources

SEC EDGAR · openFDA

last refreshed 28m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Active trials

phase1Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorderrecruitingn=140
phase2Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar Disordercompletedn=33
phase4Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disordercompletedn=29
phase3Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY II)completedn=151
phase2A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.completedn=98
phase3Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)completedn=452
phase3Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY III)terminatedn=13
phase2Dexmedetomidine in the Treatment of Symptoms Of Acute Opioid Withdrawalcompletedn=225

more trials →

$BTAI1.1000-20.29%

Insider activity

source: SEC Form 4

routine RSU / option mechanics (6)

Mar 15, 26option exerciseMehta Vimal · CEO and President219 sh
Mar 15, 26option exerciseMehta Vimal · CEO and President219 sh
Mar 15, 26option exerciseSteinhart Richard I · Chief Financial Officer35 sh
Mar 15, 26option exerciseSteinhart Richard I · Chief Financial Officer35 sh
Mar 15, 26option exerciseRodriguez Javier · See Remarks35 sh
Mar 15, 26option exerciseRodriguez Javier · See Remarks35 sh